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Abstract
Activation-induced cytidine deaminase (AID) is believed to initiate somatic hypermutation (SHM) by deamination of
deoxycytidines to deoxyuridines within the immunoglobulin variable regions genes. The deaminated bases can
subsequently be replicated over, processed by base excision repair or mismatch repair, leading to introduction of different
types of point mutations (G/C transitions, G/C transversions and A/T mutations). It is evident that the base excision repair
pathway is largely dependent on uracil-DNA glycosylase (UNG) through its uracil excision activity. It is not known, however,
which endonuclease acts in the step immediately downstream of UNG, i.e. that cleaves at the abasic sites generated by the
latter. Two candidates have been proposed, an apurinic/apyrimidinic endonuclease (APE) and the Mre11-Rad50-NBS1
complex. The latter is intriguing as this might explain how the mutagenic pathway is primed during SHM. We have
investigated the latter possibility by studying the in vivo SHM pattern in B cells from ataxia-telangiectasia-like disorder
(Mre11 deficient) and Nijmegen breakage syndrome (NBS1 deficient) patients. Our results show that, although the pattern
of mutations in the variable heavy chain (VH) genes was altered in NBS1 deficient patients, with a significantly increased
number of G (but not C) transversions occurring in the SHM and/or AID targeting hotspots, the general pattern of mutations
in the VH genes in Mre11 deficient patients was only slightly altered, with an increased frequency of A to C transversions.
The Mre11-Rad50-NBS1 complex is thus unlikely to be the major nuclease involved in cleavage of the abasic sites during
SHM, whereas NBS1 might have a specific role in regulating the strand-biased repair during phase Ib mutagenesis.
Citation: Du L, Dunn-Walters DK, Chrzanowska KH, Stankovic T, Kotnis A, et al. (2008) A Regulatory Role for NBS1 in Strand-Specific Mutagenesis during Somatic
Hypermutation. PLoS ONE 3(6): e2482. doi:10.1371/journal.pone.0002482
Editor: Jose Alberola-Ila, Oklahoma Medical Research Foundation, United States of America
Received February 25, 2008; Accepted May 14, 2008; Published June 25, 2008
Copyright:  2008 Du et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Swedish Research Council, the Swedish Cancer Foundation, the Swedish Society for Medicine and the ‘‘KID’’ program
of the Karolinska Institutet. A. M. Taylor acknowledges the continuing support of CR-UK.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Qiang.Pan-Hammarstrom@ki.se
Introduction
Mammalian organisms require two types of DNA recombina-
tion in order to produce functional antibody encoding genes. The
first, V(D)J recombination, mediates assembly of the variable
domains of the immunoglobulin (Ig) heavy and light chains in pre-
B cells. In the second, class switch recombination (CSR), the
constant region gene of the m heavy chain (Cm) is replaced by a
downstream CH gene, resulting in a change from IgM to IgG, IgE,
or IgA production. Both types of recombination require double-
strand breaks (DSBs) as intermediates, and mechanisms for
genomic stability, especially the non-homologous end-joining
(NHEJ) pathway(s), are utilized in these processes [1–3].
Somatic hypermutation (SHM), where point mutations are
introduced at a high rate into the Ig variable (V) genes, is another
important process that shapes the Ig repertoire. SHM and CSR
can occur independently in the germinal center but are both
initiated by a single B cell-specific factor, activation-induced
cytidine deaminase (AID) [4], probably through deamination of
deoxycytidine (dC) to deoxyuridine (dU) residues within the Ig
locus [5,6]. The initial lesion in the V genes and switch (S) regions
are, however, resolved differently, as DSBs seem not to be
prominent intermediates in SHM and one of the core NHEJ
factors, DNA-PKcs, is dispensable for this process [7]. Conversely,
single strand breaks (SSBs) or single strand nicks appear to be
associated with SHM [8–10]. At least two pathways, base excision
repair and mismatch repair, have been implicated in processing of
the dU: deoxyguanosine (dG) lesions in the V regions during SHM
[10]. However, the mechanism by which they result in a
mutagenic, rather than a faithful repair remains elusive.
Furthermore, these pathways are also involved in CSR and the
way in which they are regulated and coordinated to mediate SHM
or CSR is still not well understood.
It is evident that the base excision repair pathway operating in
SHM and CSR is largely dependent on uracil-DNA glycosylase
(UNG) [5,11], through its uracil excision activity [12]. It is not
known, however, which endonuclease acts in the subsequent step,
i.e. recognizes the abasic sites generated by UNG and converts
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them to SSBs. The obvious candidate is an apurinic/apyrimidinic
endonuclease (APE or APEX), which functions in the conventional
base excision repair. In mammalian cells, APE1 is the major APE
[13,14] and it is essential for early embryonic development in mice
[15]. A second APE, APE2, has also been identified [16] and mice
with a targeted inactivation of the APEX2 gene show thymic
atrophy and reduced number of B cells [17], suggesting that APE2
may have unique functional properties in the lymphoid system that
cannot be compensated by APE1. Recently, Guikema et al have
suggested that both APEs are involved in CSR, based on
observation that CSR and DSBs in Sm are moderately reduced
in mice deficient in APE2 or haploinsufficient for APE1 [18]. A
potential role for these factors in SHM has, however, not been
identified.
An alternative candidate, the Mre11-Rad50-NBS1 (MRN)
complex, has recently been proposed to compete with APE1 for
cleavage of abasic sites and to direct a mutagenic pathway [19].
This multi-subunit nuclease is required for telomere maintenance,
cell cycle checkpoint signaling, DNA replication, meiotic recom-
bination and repair of DSBs by homologous recombination and/
or NHEJ [20,21]. In mice, disruption of any subunit of the MRN
complex results in embryonic lethality [22–24]. In humans,
mutations in the genes encoding Mre11 and NBS1 result in two
rare chromosomal instability syndromes: ataxia-telangiectasia-like
disorder (ATLD) and Nijmegen breakage syndrome (NBS)
[25,26]. By studying B cells from these patients, we have
previously shown that CSR is less efficient when either Mre11
or NBS1 is deficient [27,28]. In addition, skewed mutation
patterns at the switch recombination junctions have been observed
in both ATLD and NBS patients, suggesting that the MRN
complex may be involved in repair/editing of DNA breaks/ends
in the S regions [27,28]. The requirement of NBS1 for efficient
CSR has also been demonstrated by analyzing NBS1-deficient
mouse B cells using a conditional knockout strategy [29,30]. In
addition to its role in CSR, the MRN complex has recently been
implicated in SHM, as hypermutation in the human B cell line
Ramos is accelerated by ectopic expression of NBS1 [31].
Furthermore, Mre11, rather than APE1, has been shown to be
associated with rearranged Ig genes in hypermutating B cells [19].
Moreover, in an in vitro assay, Mre11/Rad50 cleaves at abasic sites
within single-stranded regions of DNA [19]. To test whether the
MRN complex is indeed involved in SHM and the possibility that
it might act downstream of UNG, we analyzed the in vivo SHM
patterns in the Ig locus in cells from ATLD (Mre11 deficient) and
NBS (NBS1 deficient) patients.
Results
SHM pattern in VH3-23-Cc transcripts in ATLD patients
RNA was prepared from peripheral blood mononuclear cells
(PBMC) from 4 ATLD patients. In total, 34 distinct VH3-23-Cc
clones were generated and all clones were mutated (2–50 bp
substitutions/clone, average 22.1 bp) (Fig. 1A). Overall, the
frequency of mutations in the VH3-23 genes derived from ATLD
patients varied from 5.9% to 8.9%, which is similar to that found
in controls (3.4%-9.3%, average 6.9%; Table 1). The ratio of
replacement vs. silent (R/S) mutations in the CDRs (CDR1-2) and
FR (FR1-3) was also similar in the patient and control groups.
The distribution of mutations in the VH3-23 sequence in ATLD
patients was similar to that observed in controls (Fig. 1B) and there
was no significant difference in targeting of any of the 271
positions between patients and controls. Furthermore, no major
differences were found in the nature of base pair substitutions
between ATLD patients (753 mutations) and normal controls (750
mutations), except that there was a small, albeit significant,
increase of A to C transversions in the ATLD patients (8.8 vs.
5.3% in controls, x2 test, p,0.01).
To search for a potential cause for the increased frequency of A
to C transversions in ATLD patients, we analyzed the frequency of
mutations in each of the 64 possible trinucleotide combinations.
Significantly increased targeting of the A residues was observed in
AGA, CAA and CGA, whereas significantly decreased targeting of
A was noticed in CTA (Table S1). These trinucleotides are neither
related to the AID targeting (WRC/GYW) (W, A or T; R, A or G;
Y, C or T) motifs, nor the SHM hotspot motifs (RGYW/WRCY),
and no difference in targeting of the A residues within these motifs
could be observed between ATLD patients and controls (Table 2
and Table S3). Two of these trinucleotides, CAA and CTA, are
related to the previously described SHM hotspots (WA/TW) for
A/T mutations [32]. There was indeed a significantly decreased
targeting of the A residues in the TA motifs (9.2% vs. 13.3%, x2
test, p,0.05) and a small, but not significant, increase in targeting
of the AA motifs (7.2% vs. 5.3%) in ATLD patients. The
frequency of A to C transversions was, however, increased in both
the TA and AA motifs (35% vs. 21% of total A mutations within
the TA and 44% vs. 23% within the AA motifs), and also outside
these motifs (34% vs. 22%). We thus conclude that the frequency
and distribution of mutations in the VH regions are normal in
ATLD patients. The general pattern of base substitutions was
slightly altered, with an increased frequency of A to C
transversions. This alteration was, however, not associated with
differential targeting of any of the known SHM hotspots.
SHM pattern in VH3-23-Cc transcripts in NBS patients
RNA samples from 6 NBS patients (NBS1-6) were subsequently
analyzed. In total, 74 distinct VH3-23-Cc clones were obtained and a
majority of these clones were mutated (2–28 bp substitutions/clone,
average 11.2 bp; Fig. 1A). The frequency of mutations in the VH3-23
genes derived from NBS patients varied from 2.4% to 5.2%, with an
average of 4.1%, which was lower than in the controls (3.4%–9.3%,
average 6.9%, Table 1). The ratio of R/S mutations in the CDRs
and FRs was within the normal range in most patients, except in
NBS6, where nearly all the observed mutations in the CDR regions
were replacements (Table 1).
The distribution of mutations observed in NBS patients was
largely similar to that found in normal controls, with major hot
spots of mutation at previously described RGYW/WRYC motifs
(AGCT at position 72 and 129 and AGCA at position 150;
Fig. 1B). However, a slight increase, albeit significant, number of
mutations was observed at these three hotspots in NBS patients
(11.2% vs. 8.0% of total mutations, x2 test, p,0.05). In addition,
we also found a significantly increased targeting at a few positions
that are normally not highly mutated in the VH genes (AGCT,
TAG, and AAC at positions 84, 135 and 211; Fig. 1B).
Furthermore, the general pattern of base substitution in the NBS
patients (829 mutations) was somewhat different from that in
controls (750 mutations), with significantly more transversions
(49.3% vs. 44.3%, x2 test, p,0.05) and substitutions occurring at
G residues (41.4% vs. 35.6%, x2 test, p,0.05; Fig. 1C). These
were mainly due to an increased frequency of G transversions
(20.4% vs. 14.3%, x2 test, p,0.01), especially G to C
transversions, in the NBS patients (16.6% vs. 10.9%, x2 test,
p,0.01; Fig. 1C and 1D). There seems to be a gain of strand
polarity at G/C pairs in the V region in NBS patients, where the
G residues on the top (non-transcribed, coding) strand were
preferred targets for mutations (G/C ratio 1.9 vs. 1.4 in controls;
x2 test, p,0.05). The strand preference at A/T pairs was,
however, not affected (A/T ratio 1.7 vs. 1.8 in controls).
Role of Mre11 and NBS1 in SHM
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Figure 1. Pattern of mutations introduced in the VH3-23-Cc transcripts. A). Pie charts demonstrate the proportion of clones carrying the
indicated number of mutations. B). Distribution of mutations in VH3-23 in ATLD or NBS patients (above the zero line) and in controls (below the zero
line). Nucleotides are numbered from the third base of codon 10 of the VH3-23 coding region. The percentage of mutations at each position (number
of mutations at each position / total number of mutation) is plotted and the major hotspots in controls are highlighted. Several positions that show
Role of Mre11 and NBS1 in SHM
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To search for a potential cause for the increased targeting of G
residues in NBS patients, we first analyzed the sequences
surrounding individual mutated bases (22 to +2) in the VH3-23
genes. The preferred target motif for G mutation was TAGYW for
both patients and controls, confirming the known hotspots for G
mutations (RGYW/WRCY). We subsequently performed a
similar analysis as described above for the targeting of trinucle-
otides (Table S2). Significantly increased targeting of the G
residues was observed in AGC, GCA, GCT and TAG in the VH3-
23 genes in the NBS patients.
As the first three trinucleotides are all related to the AID
targeting (WRC/GYW) and/or SHM hotspot motifs for G/C
mutations (RGYW/WRCY), we subsequently analyzed the
frequency of G mutations within, or outside, these motifs. A
significantly higher number of G mutations was indeed observed
in the WRC or GYW motifs in NBS patients (Fig. 2 and Table 2),
whereas G residues outside these motifs were targeted equally
(11.3% vs. 11.1% of total mutations in controls). The G mutations
occurring in the overlapping WRC and GYW motifs (WGCW)
were, however, counted twice when analyzing the WRC and
GYW motifs separately. When this was taken into account, an
increased targeting of the G nucleotides within the GYW motifs
(including those within the overlapping motifs) could explain most
of the difference between NBS patients and controls in terms of
targeting of the G residues (Table 2), and most of the G mutations
within the WRC motifs were actually located within the
palindromic sequence WGCW. Furthermore, within the GYW
motifs, the proportion of G to C transversions was significantly
higher in NBS patients (38.3% vs. 27.1% of the total G mutations
within these motifs, x2 test, p,0.05). Similar results were obtained
when analyzing the RGYW/WRCY motifs, where an increased
targeting of the G nucleotides within the RGYW motifs (including
the ‘‘dual’’ motif AGCT) could explain most of the difference
between NBS patients and controls (Table S3).
Table 1. Mutations in VH3-23-Cc transcripts from PMBC from NBS and ATLD patients.
Clones Mutations in V region
Clustering
ratio R/S
Age (yr) Germline mutation All Distinct Unmutated Total % bp CDR/FRa CDRs FRs
ATLD patients
ATLD1 36 1897T.C (ho) 19 13 0 270 7.7 1.4 3.4 1.9
ATLD2 29 1897T.C (ho) 14 9 0 216 8.9 1.3 5.1 2.2
ATLD3 23 350G.A (he), 1714T.C (he) 14 11 0 251 8.4 1.2 5.6 2.0
ATLD4 26 350G.A (he), 1714T.C (he) 1 1 0 16 5.9 2.0 –b – b
Total (n =4) 23–36 48 34 0 753 8.2 1.3 4.5 2.0
(5.9–8.9) (1.7–2.0) (3.4–5.6) (1.9–2.2)
NBS patients
NBS1 8 657–661del5 (ho) 14 12 0 150 4.6 2.2 6.7 1.8
NBS2 10 657–661del5 (ho) 14 12 0 169 5.2 1.5 5.1 2.4
NBS3 8 657–661del5 (ho) 16 13 1 124 3.5 1.7 2.3 1.8
NBS4 6 657–661del5 (ho) 17 14 0 91 2.4 1.9 18.5 2.7
NBS5 16 657–661del5 (ho) 16 14 0 177 4.7 1.6 3.1 2.2
NBS6 2 1089C.A (ho) 18 9 2 118 4.8 1.2 36 1.8
Total (n =6) 2–16 95 74 3 829 4.1 1.7 5.0 2.1
(2.4–5.2) (1.2–2.2) (2.3–36) (1.8–2.7)
Controlsc
Total (n =5) 14–30 41 40 1 750 6.9 1.8 6.2 1.8
(3.4–9.3) (1.3–3.2) (4.5–14) (1.2–2.2)
Controls II
Total (n =7) 1–8 114 96 12 808 3.1 1.5 5.2 2.3
(1.9–4.6) (1.1–2.4) (2.5–10) (1.5–3.1)
a) CDR, complementary determining region; FR, framework region.
b) Too few mutations to give a reliable ratio.
c) The VH3-23 sequences from controls have been described previously [60].
doi:10.1371/journal.pone.0002482.t001
significantly more mutations in the NBS patients are also indicated. **p,0.01. C). Nature of the base substitutions in the VH3-23 genes. The germline
sequence used for comparison contains 21.4% A, 31.7% G, 21.4% T and 25.5% C. Correction: values presented in the column were corrected to
represent sequences with equal amounts of the four nucleotides. Statistical analysis was performed using x2 test. Numbers that are significantly
different from controls are bolded. *p,0.05; **p,0.01.q, significantly increased;Q, significantly decreased. D). Percent distribution of each type of
nucleotide substitution. Individual substitutions are paired together with their complementary mutations. Mutations in ATLD or NBS VH3-23
sequences were compared with the control VH3-23 transcripts. Stars indicate that the proportion of a given substitution when it is significantly
different in patients as compared to the controls.
doi:10.1371/journal.pone.0002482.g001
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It is interesting to note that while, on the top strand, the G
residues at the first position of the GYW or the second position of
the RGYW motifs were significantly more mutated in NBS
patients, no alteration in the rate of mutations was noted in the
corresponding C residues at the reverse complementary motifs
(WRC or WRCY; Table 2, Fig. 2 and Table S3). The C residues
within the AID hotspot in the bottom strand (39-CRW-59) seemed
to be more mutated in NBS patients, while those in the top strand
(59WRC-39) were not affected. The altered pattern of base pair
substitutions in the VH genes in NBS patients may thus arise from
asymmetric targeting of AID, or linked repair steps.
As the NBS patients are younger (2–16 years old) than the
controls (14–30 years old), we subsequently studied the frequency
and pattern of mutations in the VH3-23 genes from an additional
group of controls, aged 1–8 years. The frequency of mutations in
the VH3-23 genes derived from the second group of controls
varied from 1.9% to 4.6%, with an average of 3.1%, which is
lower as compared to the first group of controls (average 6.9%),
but comparable with the NBS patients (average 4.1%) (Table 1).
The patterns of base pair substitutions in the VH3-23 genes
derived from the two groups of controls were largely similar. When
the NBS patients were compared with the second group of
controls, we could confirm that there were significantly more G
mutations (41.4% vs. 35.9%, x2 test, p,0.05), especially G to C
transversions (16.6% vs. 12.0%, x2 test, p,0.01), in the patient
sequences (Table S4). Furthermore, the G residues at the first
position of GYW (29.3% vs. 23.0%, x2 test, p,0.01) or the second
position of RGYW (22.9% vs. 18.4%, x2 test, p,0.05) motifs were
Table 2. Number of mutations at AID targeting hotspots in VH3-23 and JH4 intronic sequences
VH3-23 sequences JH4 intronic sequences
ATLD NBS Control NBS Control
(753 mutations) (829 mutations) (750 mutations) (386 mutations) (797 mutations)
WRC
Position 1-A 42 (5.6%) 34 (4.1%) 40 (5.3%) 30 (7.8%) 42 (5.3%)
-T 14 (1.9%) 23 (2.8%)** 7 (0.9%) 11 (2.8%) 17 (2.1%)
Position 2-A 25 (3.3%) 40 (4.8%) 27 (3.6%) 5 (1.3%) 18 (2.3%)
-G 83 (11.0%) 151 (18.2%)*** 88 (11.7%) 50 (13.0%) 78 (9.8%)
Position 3-C 110 (14.6%) 126 (15.2%) 112 (14.9%) 62 (16.1%) 123 (15.4%)
Total 275 (36.5%) 375 (45.2%)*** 277 (36.9%) 158 (40.9%)* 278 (34.8%)
GYW
Position 1-G 170 (22.6%) 243 (29.3%)** 170 (22.7%) 79 (20.5%)** 107 (13.4%)
Position 2-C 82 (10.9%) 84 (10.1%) 78 (10.4%) 31 (8.0%) 70 (8.8%)
-T 20 (2.7%) 21 (2.5%) 26 (3.5%) 2 (0.5%) 7 (0.9%)
Position 3-A 59 (7.8%) 60 (7.2%) 71 (9.5%) 27 (7.0%) 31 (3.9%)
-T 19 (2.5%) 15 (1.8%) 12 (1.6%) 8 (2.1%) 23 (2.9%)
Total 350 (46.5%) 423 (51.0%) 357 (47.6%) 147 (38.1%)* 238 (29.9%)
GYW and WRC (duplicates excluded)
G mutations 186 (24.7%) 253 (30.5%)** 180 (24.0%) 87 (22.5%)** 118 (14.8%)
All sequences
G mutations 383 (37.6%) 343 (41.4%)* 267 (35.6%) 147 (38.1%)** 230 (28.9%)
doi:10.1371/journal.pone.0002482.t002
Figure 2. Frequency of mutations within the WRC/GYW motifs in VH3-23 sequences. Stars indicate that the frequency of mutations at a
given position when it is significantly different in patients as compared to controls.
doi:10.1371/journal.pone.0002482.g002
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significantly more targeted in the patients whereas targeting of the
corresponding C residues in the WRC or WRCY motifs was not
affected. We thus conclude that the frequency of mutations is still
within the normal range when NBS patients are compared to
controls with a similar age. The nature of base pair substitutions in
the VH genes in NBS patients is however altered, and these
changes are not associated with the younger age of patients.
Mutation pattern in JH4 intronic regions in NBS patients
The number of mutations (n = 7) obtained from nonproductive
NBS VH3-23 rearrangements was not sufficient for further
analysis. To exclude the possibility that the altered mutation
pattern in NBS cells was a result of selection bias introduced by
studying the expressed VH genes only, we analyzed the JH4
intronic sequences in 7 NBS (NBS6-12) patients and 10 controls.
We were able to obtain DNA samples from CD27+ PBMC in one
patient (NBS6) and nine controls, where fresh blood samples were
available. For the remaining patients and controls, DNA samples
were obtained from PBMC. More than 1750 clones were screened
and 652 clones were fully sequenced. After removing clones with
the same V(D)J junctions or JH4 intronic sequences, 279 and 175
distinct clones were obtained from the NBS patients and controls
respectively. There was a marked variation in mutation frequency
both within the patient group (0.02%–0.70%) and controls
(0.00%–2.21%), although, in general, the rate of mutations was
lower in the NBS patients (average 0.45% vs. 1.48% in controls).
However, taking into account that CD27+ cells were enriched in
the controls, the frequency of mutations in NBS patients was still
comparable to controls.
The pattern of base substitutions in the JH4 intronic regions
derived from NBS patients (386 mutations) was again different
from that in controls (797 mutations) and we confirmed that, as in
the VH3-23 transcripts, there were significantly more transversions
occurring at G residues (18.9% vs. 13.4%, x2 test, p,0.01) and G
mutations altogether (38.1% vs. 28.9%, x2 test, p,0.01). However,
unlike in the VH3-23 transcripts, increased numbers of all types of
G mutations (G to C, G to T and G to A) were observed, although
none of the individual counts reached a statistically significant
degree (Fig. 3A; x2 test, p=0.08, p=0.10 and p=0.11 respective-
ly). In addition, there were also significantly fewer A to G
substitutions in the NBS JH4 intronic sequences as compared to
those from controls (Fig. 3). The preference for G, rather than C,
residues on the top strand, a gain of strand polarity at G/C pairs,
was again notable in the NBS patient samples (G/C ratio 1.4 vs.
0.9 in controls; x2 test, p,0.05), and as in the VH sequences, the
strand preference for A/T pairs was not affected (A/T ratio 1.5 vs.
1.6 in controls). Furthermore, we could see a significant trend
where the G residues in the first position of the GYW motifs
(Table 2) or the second position of RGYW motifs (Table S3) were
more mutated in the NBS patients, whereas no difference in
targeting of the corresponding C residues in the reverse
complementary motifs (WRC or WRCY) was observed (Table 2
and S3). Thus, in NBS patients, the mutation pattern in the JH4
intronic sequences largely recaptures the features in the VH
regions, where an increased number of the G, but not C,
mutations are observed in SHM and/or AID hotspots.
Characteristics of the CDR3 in B cells from ATLD and NBS
patients
Diversity in the CDR3 region in clones derived from the ATLD
and NBS patients was also analyzed. The CDR3 contains
contributions from the VH, D, and JH gene segments and
nucleotides added by TDT. The majority of analyzable clones
were in-frame rearrangements (27 of 30 ATLD clones and 69 of
72 NBS clones). The average length of the CDR3 in the ATLD
and NBS clones was similar to those from controls (Table S5). The
length of the N regions and the number of P nucleotides in the
ATLD clones were comparable to the controls. The average
length of the N2 region (D-JH junctions) was, however,
significantly shorter in the NBS clones as compared to controls
(Student’s t test, p,0.05; Table S5) but no significant difference in
the length of the N1 regions (VH-D junction) or the frequency of P
nucleotides was observed between NBS patients and controls. We
thus conclude that the pattern of V(D)J coding joints are largely
normal in ATLD and NBS patients.
Discussion
It has previously been suggested that the MRN complex
participates in all three AID-initiated processes that diversify the Ig
genes; CSR, SHM and gene conversion. Support for the latter two
mechanisms is, however, indirect, and based on experiments using
ectopic expression of NBS1 in B cell lines [31]. ‘‘Null’’ mutations
in the gene encoding any subunit of the MRN complex result in
embryonic lethality in mice [22–24], suggesting that this complex
is essential in mammals. Cells from ATLD or NBS patients, who
carry ‘‘hypomorphic’’ mutations in the Mre11 or NBN gene, have
been used as an alternative system to analyze the functional
properties of the MRN complex in DNA damage signaling and
DNA repair, as these cells have either no, or markedly reduced
levels of the wild type proteins [33,34]. In this study, we therefore
assessed the role of the MRN complex in SHM, by analyzing the
mutational spectrum generated in vivo in VH genes in cells from
ATLD and NBS patients. Largely normal frequencies of mutations
in both groups of patients suggest that the complex is not essential
for SHM.
The first two components of the MRN complex, Mre11 and
Rad50, have been shown to have abasic site-lyase activity, with a
preference for single stranded DNA [19]. The DNA ends
produced by Mre11/Rad50 cleavage cannot directly prime new
DNA synthesis by polymerase b (pol b), which carries out high-
fidelity repair. Mre11 has therefore been proposed to compete
with APE1 for cleavage of abasic sites and to direct a mutagenic
pathway during SHM [19]. This hypothesis would predict that
Mre11 is involved in the UNG dependent pathway, which is
mainly responsible for generation of phase 1b mutations (G/C
transversions) but, together with polymerase g (pol g), also
generates a small proportion of phase II mutations (A/T
mutations) [35]. In ATLD patients (Mre11 deficient), we did
observe a perturbed mutation pattern, with a small increase of A to
C transversions (phase II). The number of G to C transversions
(phase Ib) was, however, only slightly increased and the difference
did not reach statistical significance (Fig. 1C and 1D). As the
UNG-pol g pathway probably only serves as a backup for the
MSH2-dependent pathway in phase II mutagenesis [35], one
would not expect a major change in the mutation pattern or total
mutation load at A/T bases. We would, however, expect a more
pronounced change in the rate of G/C transversions (decreased
rather than increased) in ATLD patients. Thus, Mre11 is unlikely
to be the major enzyme used to cleave the abasic sites during
SHM. Nevertheless, the increased rate of A to C transversions was
only observed in ATLD patients and, notably, these changes were
more prominent in patients ATLD1 and ATLD2, who carry
homozygous 1897 C.T (R633stop) mutations in the Mre11 gene.
The truncated Mre11 protein expressed in cells from these two
patients show weaker interaction with Rad50 as compared with
those from ATLD3 and ATLD4 [25]. As pol g is responsible for
most of the A to G and A to T substitutions, but only about 50% of
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the A to C mutations [36], an increased frequency of the latter
could indicate a lower activity of pol g and/or a higher activity of
other polymerases. Thus, the possibility remains that there is a
subtle defect in the UNG-Mre11-pol g pathway (Fig. 4). APE1
and APE2 remain the best candidates for cleavage of the abasic
sites during SHM, although direct evidence for their involvement
is still missing and potential participation of other, less well-
characterized, AP endonucleases such as PALF (PNK and APTX-
like FHA protein) also needs to be excluded [37].
The skewed mutation pattern in NBS1 deficient patients has not
been observed in any mouse or human disease model. The
alteration (increased G mutations) is closely associated with SHM
and/or AID hotspots and causes a G over C strand bias. It is
possible that, in the normal situation, NBS1 facilitates generation of
mutations from the C residues on the top strand or prevents
mutations of the deaminated C residues on the bottom strand.
Potentially, in the presence of NBS1, the top strand (non-
transcribed, coding) is more targeted by AID than the bottom
strand (transcribed, non-coding), or maybe a deaminated C residue,
located on the top strand, is processed differently from one located
on the bottom strand (mutagenically repaired or faithfully repaired).
Based on data from UNG and Msh2 double knockout mice, it has
been suggested that AID deaminates the top and bottom strands
equally well [5,38]. If this is true (there is still some debate [39]),
NBS1 is more likely to be involved in, or regulating, a strand-specific
mutagenic repair step after the initial AID targeting.
When NBS1 was overexpressed in the human B cell line
Ramos, an increased frequency of mutations in the VH genes was
observed [31]. The mutation spectrum was also altered, with
proportionally more C than G mutations [31]. This may suggest
that NBS1 facilitates generation of mutations from the C residues
in the top strand. However, in our NBS patients (NBS defective),
the mutation frequency in general is largely normal, and although
an increased number of G mutations was observed in the GYW
motifs (AID hotspots in the bottom strand), the frequency of
mutations at the C residues in the top-strand hotspot (WRC) was
not altered. Thus, based on our in vivo data, NBS1 is more likely to
influence the outcome of deaminated C residues in the bottom
strand (faithfully repaired or mutated), rather than to promote
generation of mutations from the top strand.
How might then NBS1 be regulating the mutagenic repair in
the bottom strand? One possibility is that by regulating the S phase
checkpoint and interacting with the DNA replication machinery
[40–43], NBS1 inhibits abasic site bypass DNA synthesis by
certain translesion synthesis polymerases, if the abasic sites are
located in the bottom strand (Fig. 4). When NBS1 is defective,
these polymerases will be able to bypass the DNA lesion in the
bottom strand as well, by incorporating a base opposite an abasic
site. Rev1 could be one such polymerase, which inserts a C
opposite an abasic site. In its absence, the C to G transversions are
completely absent on the top strand, but only partially reduced on
the bottom strand, suggesting that it has a preference for the top
strand [44]. Thus, a loss of strand preference of Rev1 could
explain the ‘‘net’’ increase of G to C transversions (i.e. C to G
transversions on the bottom strand) in the VH genes in NBS
patients. Alternatively, following cleavage of the abasic site by
APE, NBS1 inhibits the action of low-fidelity polymerases, if the
abasic site is located on the bottom strand (Fig. 4). In addition to
Figure 3. Pattern of mutations introduced in the JH4 intronic sequences. A). Nature of the base substitutions in the JH4 intronic genes. The
germline sequence used for comparison contains 17.9% A, 32.1% G, 17.5% T and 32.5% C. Correction: values presented in the column were corrected
to represent sequences with equal amounts of the four nucleotides. Statistical analysis was performed using x2 test. Numbers that are significantly
different from controls are bolded. *p,0.05; **p,0.01. B). Percent distribution of each type of nucleotide substitution. Stars indicate that the
proportion of a given substitution is significantly different in NBS patients as compared to that in controls.
doi:10.1371/journal.pone.0002482.g003
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the above hypothesis that NBS1 is involved in, or regulating the
‘‘post-UNG’’ events during base-excision repair, the possibility
that it interacts with the mismatch repair pathway should also be
considered. The MSH2-dependent mismatch repair pathway can
recognize the dU:dG lesions and it is responsible for generating
small proportion of the G/C mutations, including G/C transver-
sions [35]. Perhaps NBS1 can direct the choice of which of the
strands is being removed by mismatch repair [45] (Fig. 4).
Regardless of the mechanism involved, our data suggests that
transversions at G/C residues (phase Ib mutations) are also
generated in a strand-biased manner. NBS1 may be regulating this
process by promoting error-free repair on the bottom strand.
Most of the NBS patients included in this study carry a deletion
mutation (675del5), which was originally regarded as a null
mutation. Later, it was shown that in addition to the predicted
NBS1 p26 protein, through alternative translation, another
truncated protein, NBS1 p70 is produced by the patient cells
[46]. This protein lacks the N-terminal FHA and BRCT domains
but can still associate with Mre11/Rad50 and is probably
responsibe for the cell viability [46,47]. As the G/C mutation
pattern in ATLD patients is largely normal, the role of NBS1 in
SHM is probably uncoupled from Mre11. As the level of NBS1 is
also decreased in cells from the ATLD patients included in this
study (ATLD1-4) [25,48], the moderately increased rate of G to C
transversions noted might be a consequence of a reduced level of
NBS1, rather than deficiency of Mre11.
The mutation pattern at the CSR junctions was altered in both
the NBS and ATLD patient groups [27]. In ATLD patients, there
Figure 4. Hypothetical model for strand-biased mutagenic repair during SHM. AID is believed to initiate SHM through deamination of the
dC residues, probably on both strands. In phase Ia, replication over dU, without repair, creates G/C transitions [5]. In phase Ib, removal of the uracil by
UNG produces an abasic site that can be cleaved by an APE and subsequently repaired by low-fidelity polymerases, leading to transitions as well as
transversions at G/C residues. Alternatively, mutations at G/C residues might arise if a bypass DNA polymerase inserts a base opposite to an abasic
site before the lesion has been recognized by APE. The mismatch repair pathway may contribute a small fraction of phase Ib mutation although the
exact mechanism is not known. During phase Ib, NBS1 promotes error-free base-excision repair and inhibits the abasic site bypass DNA synthesis or
low-fidelity base excision repair, if the abasic site is located in the bottom strand. In phase II, mutations are introduced at adjacent positions,
predominantly at nearby A/T pairs, mainly through a MSH2/MSH6 triggered, error-prone, patch repair process. Based on the study by Unniraman et al
[62], the top-strand deaminated C residues contribute to most of the mutations at A/T residues. The low-fidelity base excision pathway, together with
pol g, may contribute a small proportion of the A/T mutations and Mre11 might be involved in this minor pathway. Base alterations are shown in red.
AP, abasic site.
doi:10.1371/journal.pone.0002482.g004
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were fewer base substitutions due to transitions and, most
strikingly, the substitutions that occurred most often in controls,
C to T transitions, never occurred [27]. In NBS patients, base
substitutions were only observed at the G/C nucleotides, with a
preference for transitions [27]. These peculiar patterns of base
substitutions at CSR junctions were, however, quite different from
the patterns we observed in the VH regions from these patients.
Thus, although the MRN complex might be involved in both CSR
and SHM, the underlying mechanisms could be quite different.
For instance, the role of the MRN complex during CSR could be
attributed to its activity in the ATM signaling pathway [49,50], or
through its interaction with the NHEJ pathway. This would,
however, not explain the role of the MRN complex in SHM, as
the ATM dependent signaling and the classical NHEJ pathway are
critical for CSR [28,51–54], but not for SHM [7,55].
In summary, the SHM mutation pattern in the VH genes in
NBS patients was altered, with a significantly increased number of
G transversions occurring in the SHM and/or AID targeting
hotspots. The general pattern of mutations in the VH genes in
ATLD patients was slightly altered, with an increased frequency of
A to C transversions. Mre11 is thus unlikely to be the major
enzyme used to cleave abasic sites, whereas NBS1 might have an
Mre11-independent role in regulating the strand-specific muta-
genic repair process during SHM, although the actual mechanism
remains elusive.
Materials and Methods
Patient material
The study included 4 ATLD patients from two independent
families and the clinical details of these patients have been
described previously [25]. The mutations in Mre11 in these
patients are shown in Table 1. The study also included 11 Polish
NBS patients (NBS1-5, NBS7-12) and 1 Pakistani NBS patient
(NBS6). The diagnosis of these patients was carried out in the
respective centers in the Children’s Memorial Health Institute
(Poland) and the Newcastle General Hospital (UK). The
truncating 5-bp deletion (657del5) in the NBN gene is present in
a homozygous form in patients NBS1-5 and NBS7-12, whereas a
homozygous nonsense mutation (1089C.A) has been identified in
NBS6 [56]. NBS1-5 and 7–12 showed reduced serum levels of IgG
or IgG subclasses and/or IgA and severely impaired specific
antibody responses after vaccination against HBV [57]. NBS6 (p1
in the original report) had hypogammaglobulinaemia and the
tetanus and HiB antibody response after immunization was poor
or absent [56]. The institutional review board at the Karolinska
Institute approved the study.
RNA isolation and PCR amplification of VH3-23-Cc
transcripts
For NBS patients and controls, total RNA was extracted from
PBMC using RNeasy RNA purification kits (Qiagen, Germany)
and first-strand cDNA synthesis was performed with a CcA primer
(59-GTCCTTGACCAGGCAGCCCAG-39) using a cDNA syn-
thesis kit (Pharmacia, Uppsala, Sweden). For ATLD patients, total
RNA was extracted from B cells using the UltraspecTM RNA
isolation system (Biotex). cDNA was synthesized using a Revers-iT
cDNA synthesis kit (AbgeneTM). The primers used for amplifica-
tion of VH3-23-Cc transcripts were VH3-23 (59-tctagaGGCT-
GAGCTGGCTTTTTCTTGTGG-39) and CcB (59-cagtcga-
cAAGA CCGATGGGCCCTTGGTGG-39). The oligonucleo-
tides contained a restriction site, (underlined, a Xba I site in the
VH3-23 primer and a Sal I site in the CcB primer) for directional
cloning of the PCR products. Amplification was performed in 35
cycles, each cycle consisting of 94uC 50 sec, 62uC 1 min and 72uC
1 min. High fidelity DNA polymerases Vent (New England
BioLabs, Hertfordshire, England, GB) or Pfu (Fermentas Life
Sciences, Burlington, Canada) were used for the amplification.
PCR amplification of JH4 intronic region sequences
PBMCs were isolated by density gradient centrifugation and
CD27+ cells were separated from PBMCs using CD27 MicroBe-
ads and a MiniMACS Separator (Miltenyi Biotec, CA, USA). The
JH4 intronic regions were PCR amplified from genomic DNA
prepared from PBMC or CD27+ PBMC (when fresh blood
samples were available) using a FR3 consensus primer and a
primer upstream of JH5 as described previously [58]. A Xba I or a
Sal I site was added in the JH4-FR3 or JH5 primer for directional
cloning of the PCR products. A long PCR kit (Expand Long
Template PCR System Kit, Roche Diagnostics Scandinavia,
Bromma, Sweden) was employed to amplify the JH4 intronic
region in the first set of controls. This system uses an enzyme
mixture containing Taq DNA polymerase and a proofreading Pwo
DNA polymerase. The PCR error was estimated to be 2/10000 bp
[55]. A high fidelity DNA polymerase Pfu (Fermentas Life
Sciences) was used in amplifications of the JH4 intronic regions
from NBS patients and a second set of controls. Genomic DNA
from several individuals with known germline TNFRSF13B
sequences were used to assess the fidelity of this polymerase.
Independent PCR products were cloned, and mutations were
shown to be introduced at a rate of less than 1/10000 bp in 37
clones analyzed (1 error of the 18027 bp sequenced). There was no
significant difference in frequency of mutations and base
substitution pattern in the two sets of controls (190 and 425
mutations respectively) and they were thus merged as one group.
Analysis of VH-Cc and JH4 clones
The PCR products were purified and cloned into the Bluescript
II KS (+) vector (Stratagene, La Jolla, USA) and transformed into
JM 109 competent cells. The resulting clones were screened by
PCR amplification (VH3-23 and CcB or JH4-FR3 and JH5) and
positive clones were sequenced by an automated fluorescent
sequencer in MWG (Ebersberg, Germany) or in Macrogen (Seoul,
Korea). The VH-Cc sequence analysis was performed by IMGT/
V-QUEST (http://imgt.cines.fr) [59] to align the VH-CcB
sequences to their closest germline VH, D and JH segment
counterparts. The immunoglobulin V(D)J junctional sequences
were analyzed by the IMGT/JunctionAnalysis tool (http://imgt.
cines.fr). The analysis on JH4 intronic sequences was performed
using the LASERGENE software package (DNASTAR, Madison,
WI, USA).
Sequence motifs surrounding mutated bases and trinucleotide
targeting were determined as previously described [60,61]. Briefly,
mutated VH3-23 or JH4 intron sequences were aligned beneath the
germline VH3-23 or JH4 intron region gene and a raw test file of
the alignment was created. This file was imported into a Microsoft
Excel spreadsheet and computations of the number of each type of
nucleotide substitution and the composition of the flanking
sequences around these substitutions were performed using macros
in Excel (Visual Basic). Computations of percentage differences
and x2 analysis were also performed using Excel.
Online Supplemental Material
Table S1 and S2 show the number of mutations at each base of
all trinucleotides in ATLD or NBS patients. Table S3 shows the
frequency of mutations within the RGYW/WRCY motifs in VH3-
23 and JH4 intronic sequences in patients and controls. Table S4
shows the nature of base pair substitutions in NBS patients and
Role of Mre11 and NBS1 in SHM
PLoS ONE | www.plosone.org 9 June 2008 | Volume 3 | Issue 6 | e2482
controls with younger ages (Control II, 1–8 years). Table S5 shows
the characteristics of the CDR3 regions in VH3-23-Cc transcripts
from ATLD and NBS patients.
Supporting Information
Table S1 Number of mutations at each base of all trinucleoti-
desa in ATLD patients
Found at: doi:10.1371/journal.pone.0002482.s001 (0.09 MB PDF)
Table S2 Number of mutations at each base of all trinucleoti-
desa in NBS patients
Found at: doi:10.1371/journal.pone.0002482.s002 (0.08 MB PDF)
Table S3 Number of mutations at SHM G/C mutation hotspots
in VH3-23 and JH4 intronic sequences
Found at: doi:10.1371/journal.pone.0002482.s003 (0.06 MB PDF)
Table S4 Comparison of the nature of base substitutions in the
VH3-23
Found at: doi:10.1371/journal.pone.0002482.s004 (0.07 MB PDF)
Table S5 Characteristics of the CDR3 regions in VH3-23-Cc
transcripts from ATLD and NBS patients
Found at: doi:10.1371/journal.pone.0002482.s005 (0.06 MB PDF)
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